NCT03038399: A reported trial by ReveraGen BioPharma, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03038399 |
|---|---|
| Title | A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 2, 2017 |
| Completion date | April 30, 2020 |
| Required reporting date | April 30, 2021, midnight |
| Actual reporting date | April 28, 2021 |
| Date last checked at ClinicalTrials.gov | April 17, 2026 |
| Days late | None |